Login to Your Account



Onyx Will Develop Cancer Drug in $320M BTG Deal

By Catherine Hollingsworth


Monday, November 10, 2008
Onyx Pharmaceuticals Inc. took another step toward building its pipeline by licensing an anticancer compound from London-based BTG plc, in a deal that could bring in as much as $320 million for the UK company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription